AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1657528 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine (calcium entry blocker) administered intravenously after restoration of spontaneous circulation
Number of subjects: 520
Study 1657528 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously after restoration of spontaneous circulation
Number of subjects: 520
Study 6755999 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 27
Study 6755999 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenoxylate
Number of subjects: 27
Study 6755999 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 27
Study 6755999 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between Loperamide and Diphenoxylate
Number of subjects: 27
Study 30365356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose iron sucrose (400 mg monthly)
Number of subjects: 2141
Study 30365356 — intervention group
Group type: COMPARATOR
Intervention: Low-dose iron sucrose (0 to 400 mg monthly)
Number of subjects: 2141
Study 29991700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous stem cell transplantation (ASCT)
Number of subjects: 295
Study 29991700 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy (MT)
Number of subjects: 295
Study 27483130 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine immediate-release (GUAN-IR) 1-3 mg/day
Number of subjects: 207
Study 27483130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate extended-release (DMPH) 5-20 mg/day
Number of subjects: 207
Study 27483130 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (COMB)
Number of subjects: 207
Study 27483130 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 207
Study 23995585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted tipranavir
Number of subjects: 115
Study 23180066 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 0
Study 23180066 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19879013 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with cisplatin and gemcitabine (arm A)
Number of subjects: 46
Study 19879013 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with cisplatin and vinorelbine (arm B)
Number of subjects: 46
Study 19879013 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemoradiotherapy with carboplatin and paclitaxel (arm C)
Number of subjects: 46
Study 19879013 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 46
Study 19879013 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 46
Study 19879013 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B
Number of subjects: 46
Study 19879013 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm C
Number of subjects: 46
Study 19879013 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 46
Study 19189526 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking pregnant women
Number of subjects: 50
Study 19189526 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking pregnant women
Number of subjects: 50
Study 19189526 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking mothers
Number of subjects: 50
Study 19189526 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking mothers
Number of subjects: 50
Study 19189526 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood of infants born to smoking women
Number of subjects: 50
Study 19189526 — intervention group
Group type: COMPARATOR
Intervention: Umbilical cord blood of infants born to nonsmoking women
Number of subjects: 50
Study 19189526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood of smoking mothers
Number of subjects: 50
Study 19189526 — intervention group
Group type: COMPARATOR
Intervention: Cord blood of nonsmoking mothers
Number of subjects: 50
Study 19189526 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation in nonsmoking group
Number of subjects: 50
Study 19189526 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation in smoking group
Number of subjects: 50
Study 15848906 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced overall treatment time (OTT) of radiotherapy (9.5, 6.5, and 5.5 weeks)
Number of subjects: 209
Study 15848906 — intervention group
Group type: EXPERIMENTAL
Intervention: High EGFr and low E-cadherin expression
Number of subjects: 209
Study 15848906 — intervention group
Group type: EXPERIMENTAL
Intervention: High EGFr or low E-cadherin
Number of subjects: 209
Study 12612272 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief sleep intervention
Number of subjects: 156
Study 10596772 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Deep Breathing (n = 18)
Number of subjects: 46
Study 10596772 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting Breaths (n = 16)
Number of subjects: 46
Study 10596772 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 12)
Number of subjects: 46
Study 8982752 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms ethinyl oestradiol (EE)
Number of subjects: 48
Study 8982752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined pill containing 30 micrograms EE and 150 micrograms levonorgestrel (LNG)
Number of subjects: 48
Study 8982752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1290178 — intervention group
Group type: EXPERIMENTAL
Intervention: A/S 1 x 3 g (single shot)
Number of subjects: 85
Study 1290178 — intervention group
Group type: EXPERIMENTAL
Intervention: A/S 3 x 3 g
Number of subjects: 85
Study 1290178 — intervention group
Group type: EXPERIMENTAL
Intervention: A/S 3 x 3 g for 3 days (Part II)
Number of subjects: 85
Study 6374059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and lorazepam
Number of subjects: 0
Study 6374059 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 0
Study 30836781 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Contrasting with Implementation Intentions (MCII)
Number of subjects: 200
Study 30836781 — intervention group
Group type: COMPARATOR
Intervention: Control (solving simple math problems)
Number of subjects: 200
Study 28038496 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 54
Study 28038496 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 54
Study 27143742 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Bolt Dynamic Hip Plating System
Number of subjects: 100
Study 27143742 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw fixation
Number of subjects: 100
Study 24572187 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitation with pay-for-performance
Number of subjects: 0
Study 22658587 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect-regulated exercise training (2 supervised sessions and 1 unsupervised session per week for 8 weeks)
Number of subjects: 20
Study 22658587 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 20
Study 20708331 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed polyglyconate sutures
Number of subjects: 81
Study 20708331 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910 sutures
Number of subjects: 81
Study 18400808 — intervention group
Group type: EXPERIMENTAL
Intervention: N(2)O Group
Number of subjects: 394
Study 18400808 — intervention group
Group type: COMPARATOR
Intervention: N(2)O-free Group
Number of subjects: 394
Study 15805331 — intervention group
Group type: EXPERIMENTAL
Intervention: VBUS (Volumetric Bladder Ultrasound)
Number of subjects: 64
Study 15805331 — intervention group
Group type: COMPARATOR
Intervention: Conventional Catheterization (CC)
Number of subjects: 64
Study 15805331 — intervention group
Group type: EXPERIMENTAL
Intervention: VBUS
Number of subjects: 64
Study 15805331 — intervention group
Group type: COMPARATOR
Intervention: CC
Number of subjects: 64
Study 12405871 — intervention group
Group type: EXPERIMENTAL
Intervention: Contoured foam seat (CFS) used as an insert in a regular highchair
Number of subjects: 4
Study 12405871 — intervention group
Group type: COMPARATOR
Intervention: Regular highchair with a thin foam liner
Number of subjects: 4
Study 12405871 — intervention group
Group type: COMPARATOR
Intervention: Regular highchair
Number of subjects: 4
Study 10561719 — intervention group
Group type: COMPARATOR
Intervention: Cultured epithelial allografting using allogeneic cultured cells, grafted on a raw surface after palatoplasty, with a duration of 3 weeks for cell culture and 2-3 weeks for complete healing.
Number of subjects: 9
Study 10561719 — intervention group
Group type: COMPARATOR
Intervention: Push-back operation only (control group).
Number of subjects: 9
Study 8738665 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion cyclosporine
Number of subjects: 302
Study 8069603 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 46
Study 8069603 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (no PCI)
Number of subjects: 46
Study 2883677 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg zotepine
Number of subjects: 15
Study 2883677 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg zotepine
Number of subjects: 15
Study 2883677 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg zotepine
Number of subjects: 15
Study 2883677 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg clozapine
Number of subjects: 15
Study 2883677 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg clozapine
Number of subjects: 15
Study 2883677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2883677 — intervention group
Group type: EXPERIMENTAL
Intervention: CFF, skin conductance, pupillary diameter and pupillary response measurements after both compounds
Number of subjects: 15
Study 2883677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse rate
Number of subjects: 15
Study 2883677 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure
Number of subjects: 15
Study 30747632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty
Number of subjects: 122
Study 30747632 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP hernioplasty
Number of subjects: 122
Study 27098404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg or 90 mg
Number of subjects: 256
Study 27098404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 26089047 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice a day
Number of subjects: 844
Study 26089047 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast (after switching from placebo at week 16)
Number of subjects: 844
Study 26089047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initially randomized group)
Number of subjects: 844
Study 26089047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after switching to apremilast at week 32)
Number of subjects: 844
Study 26089047 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast (weeks 32-52)
Number of subjects: 844
Study 26089047 — intervention group
Group type: COMPARATOR
Intervention: Apremilast and Placebo (during the placebo-controlled period)
Number of subjects: 844
Study 23053769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal clindamycin plus dexamethasone (IVCD)
Number of subjects: 66
Study 23053769 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral therapy (COT) including pyrimethamine, sulfadiazine, folinic acid and prednisone
Number of subjects: 66
Study 23053769 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral therapy (COT)
Number of subjects: 66
Study 21770716 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSGC 25 mg
Number of subjects: 514
Study 21770716 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSGC 50 mg
Number of subjects: 514
Study 21770716 — intervention group
Group type: EXPERIMENTAL
Intervention: DPSGC 100 mg
Number of subjects: 514
Study 21770716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 19487635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 0.5 units/h
Number of subjects: 10
Study 19487635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 1.0 units/h
Number of subjects: 10
Study 19487635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 2.0 units/h
Number of subjects: 10
Study 19487635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 0.5, 1.0, and 2.0 units/h
Number of subjects: 10
Study 19487635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin infusion at 1.0 and 2.0 units/h
Number of subjects: 10
Study 16685042 — intervention group
Group type: EXPERIMENTAL
Intervention: 26% carbohydrate, low saturated fat diet
Number of subjects: 178
Study 16685042 — intervention group
Group type: COMPARATOR
Intervention: 54% carbohydrate diet
Number of subjects: 178
Study 16685042 — intervention group
Group type: EXPERIMENTAL
Intervention: 26% carbohydrate diet with higher saturated fat intake
Number of subjects: 178
Study 15292628 — intervention group
Group type: EXPERIMENTAL
Intervention: Group life review activities
Number of subjects: 80
Study 15292628 — intervention group
Group type: COMPARATOR
Intervention: Discussion activities about health (Control)
Number of subjects: 80
Study 11412294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled inverse ratio ventilation
Number of subjects: 10
Study 11412294 — intervention group
Group type: COMPARATOR
Intervention: Controlled mechanical ventilation
Number of subjects: 10
Study 9505133 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead stimulus‐blink stimulus pairings with a lead interval of 120 ms and 2000 ms
Number of subjects: 128
Study 9505133 — intervention group
Group type: COMPARATOR
Intervention: Lead stimulus change (pitch change)
Number of subjects: 128
Study 7977180 — intervention group
Group type: EXPERIMENTAL
Intervention: Group condition (G) - received self-help manuals, watched a 20-day televised series, participated in six sessions emphasizing quitting techniques and social support, and monthly peer-led support groups with incentives.
Number of subjects: 38
Study 7977180 — intervention group
Group type: COMPARATOR
Intervention: Nongroup condition (NG) - received self-help manuals and watched a 20-day televised series, but no further treatment after the initial phase.
Number of subjects: 38
Study 2489863 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching of the quadriceps muscle group before a step test
Number of subjects: 62
Study 2489863 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping warm-up only
Number of subjects: 62
Study 2489863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both stretching and stepping warm-up prior to a step test
Number of subjects: 62
Study 2489863 — intervention group
Group type: COMPARATOR
Intervention: Step test only (control group)
Number of subjects: 62
Study 30475746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial electrotherapy stimulation (CES) with Alpha‐Stim 100
Number of subjects: 40
Study 30475746 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 27609816 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18-fluorodeoxyglucose PET-assisted management
Number of subjects: 392
Study 27609816 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 392
Study 27609816 — intervention group
Group type: EXPERIMENTAL
Intervention: F-18-fluorodeoxyglucose PET-assisted management (adherence to recommendations)
Number of subjects: 392
Study 23988131 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal transcranial direct current stimulation (atDCS)
Number of subjects: 40
Study 23988131 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 40
Study 22849414 — intervention group
Group type: EXPERIMENTAL
Intervention: Message that intelligence grows over time
Number of subjects: 36
Study 22849414 — intervention group
Group type: COMPARATOR
Intervention: Message that intelligence is static
Number of subjects: 36
Study 20819898 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation at 0 mg/kg per day (placebo)
Number of subjects: 285
Study 20819898 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation at 1 mg/kg per day
Number of subjects: 285
Study 20819898 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation at 2 mg/kg per day
Number of subjects: 285
Study 18284506 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective pulmonary vein isolation (SePVI)
Number of subjects: 77
Study 18284506 — intervention group
Group type: COMPARATOR
Intervention: Empirical four pulmonary vein isolation (EmPVI)
Number of subjects: 77
Study 16168734 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected Hand (AH)
Number of subjects: 19
Study 16168734 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Affected Hand (NAH)
Number of subjects: 19
Study 16168734 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 19
Study 12706640 — intervention group
Group type: EXPERIMENTAL
Intervention: ARDS patients
Number of subjects: 55
Study 12706640 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 55
Study 10674681 — intervention group
Group type: COMPARATOR
Intervention: Fansidar (3 tablets, 75 mg of pyrimethamine and 1,500 mg of sulfadoxine, a single dose on the first day)
Number of subjects: 92
Study 10674681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fansidar (3 tablets, 75 mg of pyrimethamine and 1,500 mg of sulfadoxine, a single dose on the first day) plus primaquine (30 mg a day for 14 days)
Number of subjects: 92
Study 10674681 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (30 mg a day for 14 days)
Number of subjects: 92
Study 10674681 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (200 mg once a day for 3 days) plus primaquine (30 mg a day for 14 days)
Number of subjects: 92
Study 2404389 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief infusion of intravenous heparin for less than or equal to 24 hours (group 1)
Number of subjects: 50
Study 2404389 — intervention group
Group type: COMPARATOR
Intervention: Prolonged infusion of intravenous heparin for greater than or equal to 72 hours (group 2)
Number of subjects: 50
Study 2404389 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 216238 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation
Number of subjects: 108
Study 216238 — intervention group
Group type: COMPARATOR
Intervention: Control group (only operated upon)
Number of subjects: 108
Study 29676197 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of strontium ranelate
Number of subjects: 36
Study 29676197 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of strontium ranelate
Number of subjects: 36
Study 27759067 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss interventions (low-calorie diet and bariatric surgery)
Number of subjects: 50
Study 24960665 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-SSP
Number of subjects: 370
Study 24960665 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-RFLP
Number of subjects: 370
Study 24960665 — intervention group
Group type: EXPERIMENTAL
Intervention: RQ-PCR
Number of subjects: 370
Study 24960665 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 370
Study 23602131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair testosterone measurement in men (n=24)
Number of subjects: 73
Study 23602131 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair testosterone measurement in women (n=49)
Number of subjects: 73
Study 23602131 — intervention group
Group type: COMPARATOR
Intervention: Hair testosterone levels comparison
Number of subjects: 73
Study 21036891 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg three times per day)
Number of subjects: 45
Study 21036891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18840769 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright Bodies program (intensive lifestyle program)
Number of subjects: 23
Study 18840769 — intervention group
Group type: COMPARATOR
Intervention: Clinic-care control
Number of subjects: 23
Study 17594298 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 76
Study 17594298 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended fluid intake
Number of subjects: 76
Study 17594298 — intervention group
Group type: EXPERIMENTAL
Intervention: Emesis
Number of subjects: 76
Study 15198635 — intervention group
Group type: EXPERIMENTAL
Intervention: Alphabet cues
Number of subjects: 7
Study 15198635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topic and alphabet cues
Number of subjects: 7
Study 15198635 — intervention group
Group type: EXPERIMENTAL
Intervention: Topic cues
Number of subjects: 7
Study 15198635 — intervention group
Group type: COMPARATOR
Intervention: Habitual speech (control condition)
Number of subjects: 7
Study 12066084 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracervical Foley catheter and intravaginal dinoprostone gel
Number of subjects: 339
Study 12066084 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracervical Foley catheter and 100 microg oral doses of misoprostol
Number of subjects: 339
Study 12066084 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial 100‐microg oral doses of misoprostol
Number of subjects: 339
Study 12066084 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 339
Study 9831997 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (n = 77) in flexible doses up to 200 mg
Number of subjects: 161
Study 9831997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 84)
Number of subjects: 161
Study 7521313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 150 mg/day
Number of subjects: 76
Study 7521313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 600 mg/day
Number of subjects: 76
Study 7521313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid 900 mg/day
Number of subjects: 76